Vimarsana
Biggest News Aggregation in the World

Page 35 - Special Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Special Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Special Access Program Today - Breaking & Trending Today

Cuba spy soon to be freed was willing to divulge US war plans in Afghanistan - Vimarsana News

Cuba spy soon to be freed was willing to divulge US war plans in Afghanistan

Ana Belén Montes, who went from being a highly respected analyst at the Defense Intelligence Agency for almost 17 years to being sentenced to 25 years in federal prison for conspiracy to commit espionage, is set to leave prison on Jan. 6.

Quebec first province to cover costs of psilocybin-assisted psychotherapy: Report - Vimarsana News

Quebec first province to cover costs of psilocybin-assisted psychotherapy: Report

Canadian non-profit says two doctors have successfully billed the province of Quebec after completing psilocybin-assisted psychotherapy treatment for a patient…

Terminal cancer patient has waited 440 days for federal permission to continue magic mushroom therapy - Vimarsana News

Terminal cancer patient has waited 440 days for federal permission to continue magic mushroom therapy

Thomas Hartle, a Saskatoon man with terminal cancer, hopes he can legally continue using magic mushrooms to cope with his fear of dying.

Source: cbc.ca
Canadian with cancer has been waiting over a year to access psilocybin - Vimarsana News

Canadian with cancer has been waiting over a year to access psilocybin

Thomas Hartle, an IT professional and father of two from Saskatoon, has been living with a terminal diagnosis since 2016

Cancer Patients Struggle to Access Psilocybin Before They Die - Vimarsana News

Cancer Patients Struggle to Access Psilocybin Before They Die

The legal fight to expand access to psilocybin has been gaining momentum in the US and Canada. Dying patients are leading the charge. But some remain concerned about the broader reach.